Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts $35.66 +0.15 (+0.42%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$35.67 +0.02 (+0.04%) As of 05/23/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ultragenyx Pharmaceutical Earnings Summary Ultragenyx Pharmaceutical released Q1 2025 earnings on May 6, 2025, reporting an EPS of -$1.57, which missed the consensus estimate of -$1.54 by $0.03. Quarterly revenue rose 28.0% year-over-year to $139.29 million, below analyst estimates of $145.98 million. With a trailing EPS of -$5.88, Ultragenyx Pharmaceutical's earnings are expected to grow next year, from ($5.18) to ($3.22) per share. Upcoming Q2 Earnings DateAug. 7After Market ClosesEstimatedConsensus EPS (May. 6) -$1.54 Actual EPS (May. 6) -$1.57 Missed By -$0.03 Actual Revenue (May. 6) $139.29MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)RARE Upcoming EarningsUltragenyx Pharmaceutical's next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get Ultragenyx Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ultragenyx Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRARE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RARE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ultragenyx Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20253-$1.39-$1.09-$1.23Q2 20253-$1.29-$1.08-$1.16Q3 20253-$1.39-$0.91-$1.11Q4 20253-$1.21-$0.81-$0.99 FY 2025 12 -$5.28 -$3.89 -$4.49 Q1 20261-$0.35-$0.35-$0.35Q2 20261-$0.24-$0.24-$0.24Q3 20261-$0.19-$0.19-$0.19Q4 20261-$0.04-$0.04-$0.04 Ultragenyx Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/7/2025(Estimated)--------5/6/2025Q1 2025-$1.54-$1.57 -$0.03-$1.57$145.98M$139.29M2/13/2025Q4 2024-$1.32-$1.39 -$0.07-$1.39$163.23M$164.88M11/5/2024Q3 2024-$1.45-$1.40+$0.05-$1.40$135.28M$139.49M8/1/2024Q2 2024-$1.64-$1.52+$0.12-$1.52$123.20M$147.03M5/2/2024Q1 2024-$1.72-$2.03 -$0.31-$2.03$116.03M$108.83M2/15/2024Q4 2023-$1.65-$1.52+$0.13-$1.52$119.38M$127.39M11/2/2023Q3 2023-$2.08-$2.23 -$0.15-$2.23$99.38M$98.05M8/3/2023Q2 2023-$2.11-$2.25 -$0.14-$2.25$107.10M$108.30M Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions When is Ultragenyx Pharmaceutical's earnings date? Ultragenyx Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 7th, 2025 based off last year's report dates. Learn more on RARE's earnings history. What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical issued an update on its FY 2025 earnings guidance on Tuesday, May, 6th. The company issued revenue guidance of $640.0 million-$670.0 million, compared to the consensus revenue estimate of $655.8 million. Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) missed the analysts' consensus estimate of ($1.54) by $0.03 with a reported earnings per share (EPS) of ($1.57). Learn more on analysts' earnings estimate vs. RARE's actual earnings. How can I listen to Ultragenyx Pharmaceutical's earnings conference call? The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Ultragenyx Pharmaceutical's conference call transcript? The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $590.69 million. How much profit does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$569.18 million. RARE has generated -$5.88 earnings per share over the last four quarters. What is Ultragenyx Pharmaceutical's EPS forecast for next year? Ultragenyx Pharmaceutical's earnings are expected to grow from ($5.18) per share to ($3.22) per share in the next year. More Earnings Resources from MarketBeat Related Companies GMAB Earnings RDY Earnings VTRS Earnings MRNA Earnings ASND Earnings QGEN Earnings ROIV Earnings RVMD Earnings ELAN Earnings BPMC Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? This page (NASDAQ:RARE) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
